Amedisys, Inc is a medical care facilities business based in the US. Amedisys shares (AMED) are listed on the NASDAQ and all prices are listed in US Dollars. Amedisys employs 21,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Amedisys
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AMED – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Amedisys stock price (NASDAQ: AMED)Use our graph to track the performance of AMED stocks over time.
Amedisys shares at a glance
|Latest market close||$258.37|
|52-week range||$216.20 - $325.12|
|50-day moving average||$255.21|
|200-day moving average||$269.65|
|Wall St. target price||$330.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$6.06|
Buy Amedisys shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Amedisys stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Amedisys price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-1.13%|
|3 months (2021-04-30)||-4.25%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is Amedisys under- or over-valued?
Valuing Amedisys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amedisys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amedisys's P/E ratio
Amedisys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Amedisys shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Amedisys's PEG ratio
Amedisys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amedisys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amedisys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $270.3 million.
The EBITDA is a measure of a Amedisys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.1 billion|
|Operating margin TTM||11.31%|
|Gross profit TTM||$911.2 million|
|Return on assets TTM||9.93%|
|Return on equity TTM||27.68%|
|Market capitalisation||$8.3 billion|
TTM: trailing 12 months
Shorting Amedisys shares
There are currently 709,391 Amedisys shares held short by investors – that's known as Amedisys's "short interest". This figure is 4.1% up from 681,636 last month.
There are a few different ways that this level of interest in shorting Amedisys shares can be evaluated.
Amedisys's "short interest ratio" (SIR)
Amedisys's "short interest ratio" (SIR) is the quantity of Amedisys shares currently shorted divided by the average quantity of Amedisys shares traded daily (recently around 289547.34693878). Amedisys's SIR currently stands at 2.45. In other words for every 100,000 Amedisys shares traded daily on the market, roughly 2450 shares are currently held short.
However Amedisys's short interest can also be evaluated against the total number of Amedisys shares, or, against the total number of tradable Amedisys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amedisys's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Amedisys shares in existence, roughly 20 shares are currently held short) or 0.0222% of the tradable shares (for every 100,000 tradable Amedisys shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amedisys.
Find out more about how you can short Amedisys stock.
Amedisys share dividends
We're not expecting Amedisys to pay a dividend over the next 12 months.
Have Amedisys's shares ever split?
Amedisys's shares were split on a 4:3 basis on 4 December 2006. So if you had owned 3 shares the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Amedisys shares – just the quantity. However, indirectly, the new 25% lower share price could have impacted the market appetite for Amedisys shares which in turn could have impacted Amedisys's share price.
Amedisys share price volatility
Over the last 12 months, Amedisys's shares have ranged in value from as little as $216.2046 up to $325.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amedisys's is 0.5686. This would suggest that Amedisys's shares are less volatile than average (for this exchange).
Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia.
Stocks similar to Amedisys
Amedisys in the news
Amedisys management to meet virtually with Truist
Bell State Bank & Trust Buys Campbell Soup Co, Rio Tinto PLC, Huntington Bancshares Inc, Sells Corning Inc, U.S. Bancorp, Archer-Daniels Midland Co
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Frequently asked questionsWhat percentage of Amedisys is owned by insiders or institutions?
Currently 1.514% of Amedisys shares are held by insiders and 89.016% by institutions. How many people work for Amedisys?
Latest data suggests 21,000 work at Amedisys. When does the fiscal year end for Amedisys?
Amedisys's fiscal year ends in December. Where is Amedisys based?
Amedisys's address is: 3854 American Way, Baton Rouge, LA, United States, 70816 What is Amedisys's ISIN number?
Amedisys's international securities identification number is: US0234361089 What is Amedisys's CUSIP number?
Amedisys's Committee on Uniform Securities Identification Procedures number is: 023436108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert